Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Consolidated revenue from operations stood at Rs. 111.05 crore
Subscribe To Our Newsletter & Stay Updated